Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease
Authors' conclusion
Evolocumab reduced the rate of major adverse cardiovascular event in patients with and without MVD. The benefit tended to occur earlier and was larger in patients with MVD. However, the magnitude grew over time in both groups.
Study context
- Population
- Patients with CAD in FOURIER, categorized by multivessel disease (MVD) (≥40% stenosis in ≥2 large vessels)5,887 continued into FOURIER-OLE
- Participants
- 23,656 patients
- Comparison
- Evolocumab vs placebo, by presence of multivessel disease
- Primary endpoint
- CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization
Methodological detailssubgroup analysis by MVD
- Subgroup analysis by MVD
Primary result
As reported in the abstract
Primary endpoint, by MVD subgroup
Evolocumab vs PlaceboHazard ratio (95% CI)P value
MVD: 23% risk reduction
0.77(0.68–0.87)
No MVD: 11% risk reduction
0.89(0.82–0.96)
P = 0.062for interactionSecondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Key secondary endpoint (CV death, MI, or stroke), by MVD subgroupEvolocumabvs PlaceboMVD: 31% risk reduction | 0.69 (0.59–0.81) | ||
| Key secondary endpoint (CV death, MI, or stroke), by MVD subgroupEvolocumabvs PlaceboNo MVD: 15% risk reduction | 0.85 (0.77–0.94) | P for interaction = 0.031 | |
| 0.512Hazard ratio (log scale) |
Benefit over time · first several years
- Risk reduction in MVD
- 37% to 38%
- Risk reduction without MVD
- 23% to 28%
Original publication
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease. J Am Coll Cardiol. Published 13 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →